MS Disease-Modifying Therapy: How to Choose

Research-informed explainer — last updated April 12, 2026

More than 20 disease-modifying therapies (DMTs) are now approved for multiple sclerosis, and picking one feels overwhelming — especially when neurologists themselves debate "start high and step down" versus "start moderate and escalate." The short answer: the right therapy depends on your MS type, how active your disease is, your life plans, and what risks you can accept. This is not a one-size-fits-all decision, and the best choices are made when you understand what the evidence actually says.

This explainer draws on published research from five MS specialists in the Convene directory: Jeffrey Cohen, M.D., at Cleveland Clinic, whose work on the 2010 McDonald criteria revisions established when treatment should begin [1]; Brenda Banwell, M.D., at Children's Hospital of Philadelphia, who led the 2017 McDonald criteria updates and the international pediatric MS definitions [2][3][9][10]; Peter Calabresi, M.D., now at the University of Vermont, whose NEJM review summarizes the current treatment landscape and fingolimod trial [4][6]; Robert Fox, M.D., also at Cleveland Clinic, whose Phase 3 trials established dimethyl fumarate and rituximab as high-efficacy options [5][7]; and Steven Galetta, M.D., at NYU Langone, whose AFFIRM trial analysis and natalizumab research defined the high-efficacy category [8].

What DMTs actually do

DMTs do not repair damage that has already happened. They work by reducing the frequency of new relapses and slowing the accumulation of new lesions on MRI. The goal is to preserve as much nerve and brain tissue as possible before disability mounts. None of the approved therapies cure MS, but the best of them can reduce annual relapse rates by 50 to 70 percent compared with placebo.

Across major trials, untreated relapsing-remitting MS patients experience roughly 0.5 to 1.5 relapses per year. Even a 30 percent reduction in that rate, maintained over 10 to 20 years, can meaningfully delay the transition to secondary progressive disease, which is harder to treat.

What the difference really is

DMTs fall into two broad tiers: moderate-efficacy and high-efficacy. The moderate-efficacy group includes injectable interferons (Avonex, Betaseron, Rebif), glatiramer acetate (Copaxone), and oral options like teriflunomide (Aubagio) and low-dose dimethyl fumarate (Tecfidera, Vumerity). These reduce annual relapse rates by roughly 30 to 50 percent. They have long safety records and are generally the easier choice when disease activity is low.

The high-efficacy group includes natalizumab (Tysabri), ocrelizumab (Ocrevus), ofatumumab (Kesimpta), cladribine (Mavenclad), and alemtuzumab (Lemtrada). These reduce relapses by 50 to 70 percent or more but carry more significant safety profiles. Natalizumab, for example, carries a risk of a rare but serious brain infection called PML, particularly in patients who test positive for JC virus antibodies [8].

At a glance

When each therapy tends to be used

Moderate-efficacy therapies make sense for newly diagnosed patients with mild disease activity — few or small lesions, no major disability, long gaps between any prior episodes. They give your immune system less disruption and have decades of safety follow-up.

High-efficacy therapies are appropriate when you have had two or more relapses in a year, have large or numerous new MRI lesions, had significant disability with a prior relapse, or are younger with aggressive early disease. The evidence increasingly supports starting high-efficacy treatment early in these patients, rather than waiting for injectables to fail [5].

Ocrelizumab is also approved for primary progressive MS — one of the few options for that form of the disease — based on a Phase 3 trial showing slowed disability progression. For relapsing forms, ocrelizumab reduced new MRI lesions by 94 percent compared with interferon beta in its pivotal trial [4].

What the trial data showed

The FREEDOMS trial for fingolimod enrolled 1,272 patients with relapsing MS and found a 54 percent reduction in annual relapse rate versus placebo over two years [6]. The CONFIRM trial for dimethyl fumarate enrolled 1,417 patients and found a 44 percent relapse reduction versus placebo at two years, roughly similar to glatiramer acetate in the same trial [7].

Rituximab, which targets the same CD20 pathway as ocrelizumab, was evaluated in a Phase 2 trial of 104 patients with relapsing-remitting MS. A single course reduced gadolinium-enhancing MRI lesions by 91 percent at week 24 versus placebo and cut clinical relapses substantially over 48 weeks [5]. This trial established anti-CD20 B-cell depletion as a powerful mechanism for MS control and laid the foundation for ocrelizumab's approval.

Natalizumab added to interferon beta-1a was compared with interferon alone in a 1,171-patient trial. The combination was significantly more effective for relapse reduction and MRI outcomes, though the combination is no longer used due to PML risk. The AFFIRM retrospective analysis confirmed that early natalizumab treatment preserves brain volume better than delayed treatment [8].

What is changing

The biggest shift in MS treatment strategy over the past decade is the move toward earlier high-efficacy therapy in patients with active disease, rather than the old "escalation" approach that waited for injectable therapies to fail. Multiple observational studies now show that patients who start high-efficacy drugs within the first few years of diagnosis do better long-term.

Ofatumumab, an anti-CD20 antibody that can be self-injected monthly, now offers the high-efficacy anti-CD20 pathway without the need for infusion centers. Ublituximab, another IV anti-CD20 drug with a faster infusion schedule, was approved in 2023.

Biomarker-guided decision making is also changing practice. Serum neurofilament light chain (sNfL), a marker of neuronal damage released when axons are injured, may help neurologists identify patients with subclinical disease activity who would benefit from switching therapy even without obvious clinical relapse.

Questions to ask your doctor

• Is my MS currently active based on MRI or recent relapses, and does that change which tier of therapy is right for me?
• Am I JC virus antibody-positive, and does that affect whether natalizumab is safe for me?
• If I want to start a family in the next few years, which therapies are safest to stop or continue during pregnancy?
• What does "no evidence of disease activity" (NEDA-3 or NEDA-4) mean for my treatment goal?
• How often should I get MRI scans to know if my current therapy is working?
• If I have had one or two mild relapses and stable MRI, should I consider starting a high-efficacy therapy now, or try a moderate-efficacy option first?

The bottom line

There is no single best DMT for all MS patients. The choice depends on how active your disease is, which risks you can accept, your age, pregnancy plans, and practical factors like how often you want to take medication. What the evidence does support clearly: treatment started early is more effective than treatment delayed, and patients with active disease — frequent relapses, multiple lesions, significant disability — get meaningfully better outcomes with high-efficacy therapies than with the older injectable options. The conversation with your neurologist should be specific to your MRI findings and relapse history, not just your MS diagnosis in general.